Health
Platform to predict future AF/atrial flutter nets breakthrough device designation – Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter,…
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected] to Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter, developed in collaboration with Geisinger.
The platform (Tempus ECG Analysis Platform, Tempus and Geisinger) is designated for use in patients aged 40 years and older who do not…
-
General24 hours agoAustralia’s Myanmar community mourns earthquake losses
-
Noosa News23 hours agoAustralian growers expect to benefit from US tariffs as Trump’s trade war angers markets
-
General22 hours agoPeter Dutton partially walks back public service work-from-home vow
-
Noosa News20 hours agoDisaster relief packages announced for flood-stricken western Queensland